CY1121781T1 - RASAGILLINE EXTENDED-RELEASE PHARMACEUTICAL FORM AND USES THEREOF - Google Patents
RASAGILLINE EXTENDED-RELEASE PHARMACEUTICAL FORM AND USES THEREOFInfo
- Publication number
- CY1121781T1 CY1121781T1 CY20191100699T CY191100699T CY1121781T1 CY 1121781 T1 CY1121781 T1 CY 1121781T1 CY 20191100699 T CY20191100699 T CY 20191100699T CY 191100699 T CY191100699 T CY 191100699T CY 1121781 T1 CY1121781 T1 CY 1121781T1
- Authority
- CY
- Cyprus
- Prior art keywords
- rasagilline
- extended
- release pharmaceutical
- pharmaceutical form
- pharmaceutically acceptable
- Prior art date
Links
- 238000013265 extended release Methods 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 230000003902 lesion Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- RUOKEQAAGRXIBM-UHFFFAOYSA-N n-prop-2-ynyl-2,3-dihydro-1h-inden-1-amine Chemical compound C1=CC=C2C(NCC#C)CCC2=C1 RUOKEQAAGRXIBM-UHFFFAOYSA-N 0.000 abstract 1
- 210000000653 nervous system Anatomy 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- RUOKEQAAGRXIBM-GFCCVEGCSA-N rasagiline Chemical compound C1=CC=C2[C@H](NCC#C)CCC2=C1 RUOKEQAAGRXIBM-GFCCVEGCSA-N 0.000 abstract 1
- 229960000245 rasagiline Drugs 0.000 abstract 1
- 238000013268 sustained release Methods 0.000 abstract 1
- 239000012730 sustained-release form Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychology (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Η παρούσα εφεύρεση παρέχει διάφορες φαρμακευτικές συνθέσεις, συγκεκριμένα για από του στόματος χορήγηση, συνταγοποιημένες για παρατεταμένη απελευθέρωση δραστικών ενώσεων, χρήσιμων στην θεραπεία νευροεκφυλιστικών ασθενειών, συγκεκριμένα της νόσου Parkinson και βλαβών του νευρικού συστήματος. Η δραστική ένωση που συμπεριλαμβάνεται εντός αυτών των συνθέσεων κατά προτίμηση επιλέγεται από Ν-προπαργυλ-1-αμινοϊνδάνιο, εναντιομερές αυτού ή φαρμακευτικώς αποδεκτό άλας αυτού, περισσότερο προτιμητέα ρασαγιλίνη ή φαρμακευτικώς αποδεκτό άλας αυτής.The present invention provides various pharmaceutical compositions, in particular for oral administration, formulated for sustained release of active compounds, useful in the treatment of neurodegenerative diseases, in particular Parkinson's disease and nervous system lesions. The active compound included within these compositions is preferably selected from N-propargyl-1-aminoindane, an enantiomer thereof or a pharmaceutically acceptable salt thereof, more preferably rasagiline or a pharmaceutically acceptable salt thereof.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30101910P | 2010-02-03 | 2010-02-03 | |
| PCT/IL2011/000126 WO2011095973A1 (en) | 2010-02-03 | 2011-02-03 | Extended release formulations of rasagiline and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1121781T1 true CY1121781T1 (en) | 2020-07-31 |
Family
ID=43896855
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20191100699T CY1121781T1 (en) | 2010-02-03 | 2019-07-03 | RASAGILLINE EXTENDED-RELEASE PHARMACEUTICAL FORM AND USES THEREOF |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US9943489B2 (en) |
| EP (2) | EP3517103A1 (en) |
| JP (3) | JP6045347B2 (en) |
| KR (1) | KR101791715B1 (en) |
| CN (1) | CN102791258B (en) |
| AU (1) | AU2011212068B2 (en) |
| BR (1) | BR112012019374B1 (en) |
| CA (1) | CA2789006C (en) |
| CL (1) | CL2012002175A1 (en) |
| CY (1) | CY1121781T1 (en) |
| DK (1) | DK2531181T3 (en) |
| ES (1) | ES2733133T3 (en) |
| HU (1) | HUE044221T2 (en) |
| IL (1) | IL221274A (en) |
| LT (1) | LT2531181T (en) |
| MX (1) | MX354423B (en) |
| NZ (1) | NZ602111A (en) |
| PL (1) | PL2531181T3 (en) |
| PT (1) | PT2531181T (en) |
| RS (1) | RS58988B1 (en) |
| RU (2) | RU2734632C2 (en) |
| SG (1) | SG183150A1 (en) |
| TR (1) | TR201909277T4 (en) |
| WO (1) | WO2011095973A1 (en) |
| ZA (1) | ZA201206462B (en) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TR201909277T4 (en) * | 2010-02-03 | 2019-07-22 | Pharma Two B Ltd | Rasagiline extended release formulations and uses. |
| CA2758556A1 (en) * | 2011-11-17 | 2013-05-17 | Pharmascience Inc. | Pharmaceutical composition of amphetamine mixed salts |
| US9504657B2 (en) * | 2012-01-12 | 2016-11-29 | Pharmatwob Ltd. | Fixed dose combination therapy of Parkinson's disease |
| PL2802319T3 (en) * | 2012-01-12 | 2018-04-30 | Pharma Two B Ltd. | Fixed dose combination therapy of parkinson's disease |
| CN103316026B (en) | 2012-03-23 | 2016-05-11 | 中国人民解放军军事医学科学院毒物药物研究所 | Contain joint product of Phentermine and Topiramate and preparation method thereof |
| CN102579367B (en) * | 2012-03-23 | 2014-03-12 | 中国人民解放军军事医学科学院毒物药物研究所 | Topiramate sustained-release drug composition, method for preparing same and application of Topiramate sustained-release drug composition |
| WO2013139292A1 (en) | 2012-03-23 | 2013-09-26 | 中国人民解放军军事医学科学院毒物药物研究所 | Joint product containing synephrine and topiramate |
| MX2015002062A (en) | 2012-08-17 | 2015-06-05 | Teva Pharma | Parenteral formulation of rasagiline. |
| WO2014192022A1 (en) * | 2013-05-20 | 2014-12-04 | Cadila Healthcare Limited | Pharmaceutical compositions of rasagiline |
| US20150275167A1 (en) * | 2014-03-28 | 2015-10-01 | Corning Incorporated | Composition and method for cell culture sustained release |
| CN107106494B (en) | 2014-09-15 | 2021-12-21 | 奥菲泽米有限公司 | Arilomo formulations |
| EP4327871A3 (en) * | 2017-05-19 | 2024-06-05 | Biscayne Neurotherapeutics, Inc. | Modified release pharmaceutical compositions of huperzine and methods of using the same |
| CN107049985B (en) * | 2017-06-07 | 2020-06-19 | 广州帝奇医药技术有限公司 | Long-acting sustained-release preparation of anti-Parkinson disease drug and preparation method thereof |
| KR20210014289A (en) | 2019-07-30 | 2021-02-09 | (주)비씨월드제약 | Manufacturing method of sustained release rasagiline microsphere |
| WO2022238401A1 (en) * | 2021-05-11 | 2022-11-17 | Advicenne | Prolonged-release pharmaceutical composition for oral administration of sultiame |
| CN118680910A (en) * | 2024-08-26 | 2024-09-24 | 山东齐都药业有限公司 | Pharmaceutical composition for sustained release delivery of rasagiline mesylate, preparation method and application thereof |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4166452A (en) | 1976-05-03 | 1979-09-04 | Generales Constantine D J Jr | Apparatus for testing human responses to stimuli |
| US4256108A (en) | 1977-04-07 | 1981-03-17 | Alza Corporation | Microporous-semipermeable laminated osmotic system |
| US4265874A (en) | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
| US4415547A (en) * | 1982-06-14 | 1983-11-15 | Sterling Drug Inc. | Sustained-release pharmaceutical tablet and process for preparation thereof |
| US4861800A (en) | 1987-08-18 | 1989-08-29 | Buyske Donald A | Method for administering the drug deprenyl so as to minimize the danger of side effects |
| HU208484B (en) | 1988-08-17 | 1993-11-29 | Chinoin Gyogyszer Es Vegyeszet | Process for producing pharmaceutical composition containing acid additional salt of selegilin as active component for treating schisofrenia |
| IL92952A (en) | 1990-01-03 | 1994-06-24 | Teva Pharma | R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them |
| US5744500A (en) | 1990-01-03 | 1998-04-28 | Teva Pharmaceutical Industries, Ltd. | Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof |
| US5151449A (en) | 1990-08-31 | 1992-09-29 | Deprenyl Animal Health, Inc. | Use of L-deprenyl for retention of specific physiological functions |
| CA2039194C (en) | 1990-08-31 | 1997-01-28 | Norton W. Milgram | Uses of l-deprenyl and compositions for same |
| US5225446A (en) | 1990-08-31 | 1993-07-06 | Deprenyl Animal Health, Inc. | Use of 1-deprenyl for retention of specific physiological functions |
| US5192808A (en) | 1990-08-31 | 1993-03-09 | Deprenyl Animal Health, Inc. | Therapeutic effect of L-deprenyl in the management of pituitary-dependent hyperadrenocorticism (cushing's disease) |
| US5169868A (en) | 1991-03-01 | 1992-12-08 | University Of Saskatchewan | Aliphatic propargylamines as specific mao-b inhibitors |
| JPH06506204A (en) | 1991-04-04 | 1994-07-14 | ザ・ユニバーシティ・オブ・トロント・イノベイションズ・ファウンデイション | Use of Deprenyl to maintain, prevent loss, or restore neuronal function |
| WO1992021333A2 (en) | 1991-05-24 | 1992-12-10 | Pharmavene, Inc. | Treatment of drug withdrawal symptoms and drug craving with type b monoamine oxidase inhibitors |
| IL99759A (en) | 1991-10-16 | 1997-06-10 | Teva Pharma | Mono-fluorinated derivatives of n-propargyl-1-aminoindan, their preparation and pharmaceutical compositions containing them |
| US5242950A (en) | 1992-04-23 | 1993-09-07 | Somerset Pharmaceuticals, Inc. | Treatment of macular degeneration |
| JP2916978B2 (en) * | 1993-08-25 | 1999-07-05 | エスエス製薬株式会社 | Controlled release initiation type formulation |
| IL111240A (en) * | 1993-10-18 | 2001-10-31 | Teva Pharma | Salts of r(+) - enantiomers of n- propargyl-1-aminoindan and pharmaceutical compositions comprising them |
| US6348208B1 (en) | 1995-01-13 | 2002-02-19 | Somerset Pharmaceuticals, Inc. | Methods and pharmaceutical compositions employing desmethylselegiline |
| PE57198A1 (en) * | 1996-03-25 | 1998-10-10 | American Home Prod | PROLONGED RELEASE FORMULA |
| IL118836A (en) | 1996-07-11 | 2001-01-11 | Teva Pharma | Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan |
| US6251938B1 (en) | 1996-12-18 | 2001-06-26 | Teva Pharmaceutical Industries, Ltd., | Phenylethylamine derivatives |
| WO1998027055A1 (en) | 1996-12-18 | 1998-06-25 | Teva Pharmaceutical Industries, Ltd. | Aminoindan derivatives |
| US5840979A (en) | 1997-07-14 | 1998-11-24 | University Of Saskatchewan | Aliphatic propargylamines as cellular rescue agents |
| AU4748100A (en) | 1999-04-29 | 2000-11-17 | Merck Patent Gmbh | Glycine cleavage system inhibitors as potential antipsychotics |
| EP1411901B1 (en) * | 2001-07-04 | 2010-08-18 | Sun Pharma Advanced Research Company Ltd | Gastric retention controlled drug delivery system |
| US20040076668A1 (en) | 2002-07-03 | 2004-04-22 | Pfizer Inc. | Controlled-release pharmaceutical formulations |
| AU2003290838A1 (en) | 2002-11-15 | 2004-06-15 | Teva Pharmaceutical Industries, Ltd. | Use of rasagiline with or without riluzole to treat amyotrophic lateral sclerosis |
| EP1715843A1 (en) * | 2004-01-29 | 2006-11-02 | Neuromolecular Inc. | Combination of a nmda receptor antagonist and a mao-inhibitor or a gadph-inhibitor for the treatment of central nervous system-related conditions |
| CA2574925A1 (en) | 2004-07-26 | 2006-02-09 | Teva Pharmaceutical Industries Ltd. | Pharmaceutical dosage forms including rasagiline |
| RS20070512A (en) * | 2005-06-29 | 2009-01-22 | Panacea Biotec Ltd., | Pharmaceutical sustained release compositionsand processes thereof |
| ES2566395T3 (en) * | 2005-07-28 | 2016-04-12 | Shire Llc | Pharmaceutical formulations / compositions of guanfacine suitable for single daily dose |
| EP1909767A2 (en) * | 2005-07-28 | 2008-04-16 | Supernus Pharmaceuticals, Inc. | Modified release tablet formulations with enhanced mechanical properties |
| CN101032474B (en) * | 2006-03-06 | 2011-02-16 | 重庆医药工业研究院有限责任公司 | Rasagiline transparent patch for curing and preventing neurological diseases and the preparing method thereof |
| CN101486655A (en) * | 2008-01-17 | 2009-07-22 | 美德（江西）生物科技有限公司 | Methanesulfonic acid rasagiline crystal form and preparation thereof |
| NO2303330T3 (en) | 2008-06-06 | 2018-04-14 | ||
| US20100008983A1 (en) | 2008-06-10 | 2010-01-14 | Muhammad Safadi | Rasagiline soft gelatin capsules |
| US20100041920A1 (en) * | 2008-07-18 | 2010-02-18 | Stephen Benedict David Winter | New salt forms of an aminoindan derivative |
| EP2218444A3 (en) | 2009-01-23 | 2010-08-25 | Teva Pharmaceutical Industries, Ltd. | Delayed release rasagiline formulation |
| TR201909277T4 (en) * | 2010-02-03 | 2019-07-22 | Pharma Two B Ltd | Rasagiline extended release formulations and uses. |
-
2011
- 2011-02-03 TR TR2019/09277T patent/TR201909277T4/en unknown
- 2011-02-03 EP EP19159171.8A patent/EP3517103A1/en not_active Withdrawn
- 2011-02-03 BR BR112012019374-0A patent/BR112012019374B1/en active IP Right Grant
- 2011-02-03 RU RU2016141314A patent/RU2734632C2/en active
- 2011-02-03 US US13/577,099 patent/US9943489B2/en active Active
- 2011-02-03 NZ NZ602111A patent/NZ602111A/en unknown
- 2011-02-03 HU HUE11707489 patent/HUE044221T2/en unknown
- 2011-02-03 PT PT11707489T patent/PT2531181T/en unknown
- 2011-02-03 RS RS20190810A patent/RS58988B1/en unknown
- 2011-02-03 ES ES11707489T patent/ES2733133T3/en active Active
- 2011-02-03 JP JP2012551732A patent/JP6045347B2/en active Active
- 2011-02-03 KR KR1020127023006A patent/KR101791715B1/en active IP Right Grant
- 2011-02-03 MX MX2012009079A patent/MX354423B/en active IP Right Grant
- 2011-02-03 RU RU2012136723A patent/RU2607595C2/en active
- 2011-02-03 CA CA2789006A patent/CA2789006C/en active Active
- 2011-02-03 EP EP11707489.8A patent/EP2531181B1/en active Active
- 2011-02-03 WO PCT/IL2011/000126 patent/WO2011095973A1/en active Application Filing
- 2011-02-03 SG SG2012057493A patent/SG183150A1/en unknown
- 2011-02-03 DK DK11707489.8T patent/DK2531181T3/en active
- 2011-02-03 AU AU2011212068A patent/AU2011212068B2/en active Active
- 2011-02-03 PL PL11707489T patent/PL2531181T3/en unknown
- 2011-02-03 LT LTEP11707489.8T patent/LT2531181T/en unknown
- 2011-02-03 CN CN201180012590.4A patent/CN102791258B/en active Active
-
2012
- 2012-08-02 IL IL221274A patent/IL221274A/en active IP Right Grant
- 2012-08-03 CL CL2012002175A patent/CL2012002175A1/en unknown
- 2012-08-28 ZA ZA2012/06462A patent/ZA201206462B/en unknown
-
2016
- 2016-09-26 JP JP2016186945A patent/JP6440662B2/en active Active
-
2018
- 2018-11-20 JP JP2018216973A patent/JP6770564B2/en active Active
-
2019
- 2019-07-03 CY CY20191100699T patent/CY1121781T1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1121781T1 (en) | RASAGILLINE EXTENDED-RELEASE PHARMACEUTICAL FORM AND USES THEREOF | |
| CY1119490T1 (en) | PYRAZOLOPYROLIDINE PRODUCTS AND THEIR USE IN PATIENT TREATMENT | |
| CY1120088T1 (en) | AZAZINE OR DIAZANDAZOLO TYPE PRODUCTS AS MEDICINE | |
| EA200970287A1 (en) | METHODS, COMPOUNDS, COMPOSITIONS AND MEDIA SUITABLE FOR DELIVERY OF 3-AMINO-1-PROPANSULPHONE ACID | |
| CY1119886T1 (en) | METHOD FOR MANUFACTURING OF A PHARMACEUTICAL COMPOSITION IN FORM OF PROLONGED RELEASE TABLET CONTAINING pirfenidone and uses thereof regression CHRONIC RENAL DEFICIENCY, KAPSIKIS SYSPASIS udder of hepatic INOSIS IN HUMANS | |
| CY1113108T1 (en) | LEVODOPA BASIC PRODUCT, HIS COMPOSITIONS, AND USES | |
| EA200901373A1 (en) | AMINOGETEROCYCLIC COMPOUNDS | |
| CO6361928A2 (en) | MODULAR ARIL METHYL BENZOQUINAZOLINONA POSITIVE ALLOSTERICS OF THE RECEIVER M1 | |
| JP2011102304A5 (en) | ||
| UY31405A1 (en) | "PIPERIDINO-DIHIDROTIENOPIRIMIDAS REPLACED" | |
| UY30377A1 (en) | FUSIONATED TRICYCLE INHIBITORS OF SULFONAMIDE OF GAMA-SECRETASA | |
| EA201492010A1 (en) | APPLICATION OF HIGH DOSE OF LACHINIMODE FOR TREATMENT OF MULTIPLE SCLEROSIS | |
| TN2012000421A1 (en) | Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents | |
| PE20160195A1 (en) | USE OF PRIDOPIDINE IN HIGH DOSES FOR THE TREATMENT OF HUNTINGTON DISEASE | |
| CY1117326T1 (en) | CATEGOLAMINE PRODUCT USEFUL FOR PARKINSON'S DISEASE TREATMENT | |
| UY32487A (en) | PHARMACEUTICAL COMPOSITIONS OF IMMEDIATE RELEASE UNDERSTANDING OXYCODONE AND NALOXONE | |
| MY165149A (en) | Use of binders for manufacturing storage stable formulations | |
| EA200901423A1 (en) | BENZIMIDAZOLY AND CONTAINING THEIR PHARMACEUTICAL COMPOSITIONS | |
| UY31346A1 (en) | COMPOUNDS THAT HAVE ACTIVITY IN THE RECEIVER M1 AND ITS USES IN MEDICINE | |
| CL2008001820A1 (en) | Aryl-isoxasol-imidazole derived compounds; preparation procedure; pharmaceutical composition containing them; and use in the preparation of useful drugs in the treatment of cognitive disorders and Alzheimer's-related diseases. | |
| ATE487720T1 (en) | 5,6,7,8-TETRAHYDROPTERIDINE DERIVATIVES AS HSP90 INHIBITORS | |
| MX2015001917A (en) | Pharmaceutical compositions of memantine. | |
| MA32841B1 (en) | Compounds of cyclondica dipseibeptides and their use as drugs | |
| ECSP088966A (en) | MUSCARINIC RECEIVER AGONISTS THAT ARE EFFECTIVE IN THE TREATMENT OF PAIN, ALZHEIMER'S DISEASE AND SCHIZOPHRENIA | |
| CY1114760T1 (en) | Atherosclerosis Therapeutic Treatment |